Tricistronic constructs targeting CD19, CD20, and CD22, were found to be effective in vitro and in vivo against CD19− primary B-ALL models and patient-derived ex vivo samples of patients relapsed after anti-CD19 CAR T-cells [138]. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.